TPX2 as a Novel Prognostic Indicator and Promising Therapeutic Target in Triple-negative Breast Cancer
TPX2 as a Novel Prognostic Indicator and Promising Therapeutic Target in Triple-negative Breast Cancer
复制标题
TPX2 作为三阴性乳腺癌的新型预后指标和有前景的治疗靶点
DOI：
10.1016/j.clbc.2019.05.012
复制
发表时间：
2019-12-01
影响因子：
3.1
通讯作者：
Luo, Jian
中科院分区：
文献类型：
--
作者：
Jiang, Yueqiang;Liu, Yan;Luo, Jian
爪蟾激酶样蛋白2 （TPX2）靶蛋白表达与三阴性乳腺癌（TNBC）的关系尚未得到研究。本研究中，通过TPX2免疫组化染色对确诊TNBC患者进行评估。我们的研究表明，TPX2蛋白水平升高与TNBC患者的不良预后（包括无进展生存期和总生存期）显著相关。总之，我们证明TPX2可能是TNBC无进展和总生存期的一种新的预后标志物。简介：三阴性乳腺癌（TNBC）缺乏内分泌治疗和靶向治疗，是所有乳腺癌中预后最差的，是全世界妇女最常见的恶性肿瘤。xenopus激酶样蛋白2 （TPX2）靶向蛋白是一种微管相关蛋白，与染色体不稳定性密切相关，导致不同人类肿瘤的发展。在此，我们研究了TNBC临床结局与TPX2蛋白表达水平的关系。材料与方法：首次在同济医院治疗的确诊TNBC患者通过免疫组织化学染色评估并回顾性纳入我们的研究。TPX2的免疫组化染色评价依据染色强度和程度。采用STATA对所有数据进行分析。结果：共有97例TNBC患者被纳入我们的研究。TPX2蛋白在几乎所有TNBC患者中都过表达。我们的研究表明，TPX2蛋白水平升高与TNBC患者较差的预后显著相关，包括较差的无进展生存期（PFS）和总生存期（OS） (log-rank检验，P
The relationship between targeting protein for xenopus kinesin-like protein 2 (TPX2) expression and triple negative breast cancer (TNBC) has not yet been studied. Herein, patients with confirmed TNBC are evaluated by immunohistochemical staining of TPX2. Our study reveals that elevated TPX2 protein level is significantly associated with worse outcomes, including progression-free and overall survival, in patients with TNBC. In conclusion, we demonstrate that TPX2 could be a novel prognostic marker of progression-free and overall survival in TNBC.Introduction: Triple-negative breast cancer (TNBC), which lacks endocrine therapies and targeted therapies, has the worst prognosis of all breast cancers which remain the most common malignancy in women worldwide. Targeting protein for xenopus kinesin-like protein 2 (TPX2) is a microtubule-associated protein that is strongly correlated with chromosomal instability, resulting in the development of different human tumors. Herein, we investigated the relationship between the clinical outcome of TNBC and the expression level of the TPX2 protein. Materials and Methods: Patients initially treated at Tongji Hospital for confirmed TNBC were evaluated by immunohistochemical staining and retrospectively recruited into our study. The immunohistochemical staining evaluation of TPX2 was based on the staining intensity and extent. STATA was used to analyze all the data. Results: In total, 97 patients with TNBC were recruited into our study. The TPX2 protein was overexpressed in almost all patients with TNBC. Our study demonstrated that an elevated TPX2 protein level was significantly associated with worse outcomes in the patients with TNBC, including worse progression-free survival (PFS) and overall survival (OS) (log-rank test, P